# An Evolutionary Metric for Estimating PhyloAges from Bulk Sequencing of Hematopoietic Stem Cells Reveals the Tempo of Blood Aging in Cancer and Longevity

**Authors:** Jack M. Craig, Ryan M. Tobin, Walter Wolfsberger, Taras K. Oleksyk, Sayaka Miura, Glenn S. Gerhard, Sudhir Kumar

PMC · DOI: 10.1007/s00239-025-10296-y · Journal of Molecular Evolution · 2025-12-26

## TL;DR

This paper introduces a new method to estimate blood aging using bulk sequencing data, showing it works as well as more expensive single-cell methods.

## Contribution

A new evolutionary metric derived from bulk sequencing data enables accurate phyloAge estimation without single-cell sequencing.

## Key findings

- VFS-based phyloAge estimates match those from HSC genome phylogenies.
- AML patients had phyloAges 168 years older than chronological age.
- Long-lived individuals showed lower phyloAges, suggesting reduced cancer risk.

## Abstract

The phylogeny of a person’s hematopoietic stem cells (HSCs) can be used to quantify physiological aging of blood using a phyloAge model based on diversity decay metrics. However, this procedure currently requires accurate HSC genome sequences, which are expensive and time-consuming to obtain. We show that metrics of diversity decay can be derived from the somatic variant frequency spectrum (VFS) using more affordable, routine bulk sequencing, because HSCs evolve without recombination at a clock-like rate. We found that VFS-based models produce phyloAge estimates similar to those derived from HSC genome phylogenies. Customized for protein-coding variation and sequencing read depth, VFS-based HSC phyloAge estimates were, on average, 168 years more than chronological ages in 157 patients with acute myeloid leukemia, consistent with excess HSC aging observed in cancer patients using single cell genome phylogenies. We also tested the hypothesis that variants in cancer driver genes may confer longevity, as they occur in a significant fraction of long-lived individuals. Indeed, HSC phyloAge estimates were significantly lower, consistent with reduced hematologic cancer risk among extremely old individuals. Thus, the new metrics and models broaden the utility of the phyloAge approach, making it feasible and efficient for clinical and research applications.

The online version contains supplementary material available at 10.1007/s00239-025-10296-y.

## Linked entities

- **Diseases:** acute myeloid leukemia (MONDO:0015667)

## Full-text entities

- **Diseases:** Cancer (MESH:D009369), acute myeloid leukemia (MESH:D015470)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920717/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920717/full.md

---
Source: https://tomesphere.com/paper/PMC12920717